Entrada Therapeutics, Inc.
TRDA
$6.37
$0.111.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.74M | 25.42M | 61.52M | 79.48M | 172.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.74M | 25.42M | 61.52M | 79.48M | 172.22M |
| Cost of Revenue | 141.55M | 140.57M | 141.72M | 134.61M | 128.77M |
| Gross Profit | -135.81M | -115.15M | -80.20M | -55.14M | 43.45M |
| SG&A Expenses | 40.70M | 40.85M | 41.36M | 41.03M | 39.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.25M | 181.42M | 183.08M | 175.64M | 168.11M |
| Operating Income | -176.51M | -156.00M | -121.56M | -96.16M | 4.11M |
| Income Before Tax | -165.16M | -142.83M | -104.49M | -76.91M | 23.81M |
| Income Tax Expenses | 962.00K | 924.00K | -1.04M | -3.55M | -972.00K |
| Earnings from Continuing Operations | -166.12 | -143.75 | -103.46 | -73.35 | 24.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -166.12M | -143.75M | -103.46M | -73.35M | 24.78M |
| EBIT | -176.51M | -156.00M | -121.56M | -96.16M | 4.11M |
| EBITDA | -172.56M | -151.90M | -117.36M | -92.26M | 7.89M |
| EPS Basic | -4.00 | -3.47 | -2.50 | -1.78 | 0.87 |
| Normalized Basic EPS | -2.46 | -2.13 | -1.58 | -1.17 | 0.54 |
| EPS Diluted | -4.00 | -3.47 | -2.51 | -1.79 | 0.80 |
| Normalized Diluted EPS | -2.46 | -2.13 | -1.58 | -1.17 | 0.50 |
| Average Basic Shares Outstanding | 166.24M | 165.48M | 164.72M | 163.88M | 156.73M |
| Average Diluted Shares Outstanding | 166.24M | 165.48M | 166.93M | 166.09M | 160.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |